Home·Know Your Companions™·Therapies·LYNPARZA

LYNPARZA (olaparib)

TherapyAstraZeneca, Merck

LYNPARZA (olaparib) from AstraZeneca and Merck is a PARP inhibitor used in tumors with homologous recombination repair defects.

Approvals

Indications

Biomarkers

Mapped tests

Where this therapy is approved with a companion diagnostic

Each row represents a defined combination of indication, biomarker criteria, and LYNPARZA. Select a testing pathway to see the eligible companion diagnostic tests.

Indication-specific approvals

Approvals where LYNPARZA is tied to a specific indication and biomarker definition.

Indication	Biomarker criteria
Ovarian Cancer Solid Tumor · Ovary	BRCA1 alterations (including mutations)	View testing pathway →
Breast Cancer Solid Tumor · Breast	BRCA1 alterations (including mutations)	View testing pathway →
Pancreatic Cancer Solid Tumor · Pancreas	BRCA1 alterations (including mutations)	View testing pathway →
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate	BRCA1 alterations (including mutations)	View testing pathway →
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate	Homologous recombination repair (HRR) genes BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations	View testing pathway →
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate	ATM alterations (including mutations)	View testing pathway →
Ovarian Cancer Solid Tumor · Ovary	HRD Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score	View testing pathway →

Tumor-agnostic approvals

Approvals defined at the solid tumor level where biomarker criteria determine eligibility for LYNPARZA.

No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.

Tests used in these approvals

These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering LYNPARZA for eligible patients.

Test

BRACAnalysis CDx

Myriad Genetics

Method

PCR

Specimen

Whole blood

4 approvalsView test profile →

Test

FoundationOne CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Tissue (FFPE)

2 approvalsView test profile →

Test

FoundationOne Liquid CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Whole blood

1 approvalView test profile →

Test

Myriad myChoice CDx

Myriad Genetics

Method

NGS

Specimen

Tissue (FFPE)

1 approvalView test profile →

This view is scoped to LYNPARZA (olaparib). You can also see how it compares with other therapies and indications on the main Know Your Companions™ map.